Trial Profile
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms DESTINY-CRC01
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 31 Aug 2023 According to a Daiichi Sankyo Company media release, ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designations in U.S for the treatment of patients with HER2 positive (IHC 3+) metastatic colorectal cancer who have received two or more prior regimens, based on final results from the DESTINY-CRC01 and primary results from the DESTINY-CRC02 trial.
- 22 Jan 2022 Results (Data cut off date: Dec 28, 2020) assessing the updated longer-term efficacy and safety data of T-DXd in pts with HER2-expressing mCRC showed promising antitumor activity and a manageable safety profile (cohort A median follow-up [FU], presented at the 2022 Gastrointestinal Cancers Symposium.
- 07 Sep 2021 According to a Daiichi Sankyo Company media release, the company will hold a conference call for investors and analysts on September 21, 2021 to provide an overview of the ESMO data.